Skip to content
DataLookout
Menu

IRISNCT07836101

Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Notable Start date pushed from Oct 2026 to Dec 2026
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety as assessed by Absence of any grade ≥2 Immune Related Adverse Event (irAE)
Timeframe: From enrollment to the end of treatment at 53 weeks

Secondary (4)

Safety and tolerability as assessed by occurrence of adverse events
Absence of Serious immune-related adverse event
Efficacy as assessed by progression free survival
Efficacy as assessed by Overall survival

Arms and interventions

Sarilumab with ICIExperimental

Sarilumab is dosed 200 mg subcutaneously every two weeks for a total of 24 weeks. ICI will be dosed by investigator's choice per standard of care for malignancy. ICI will be administered on day 1 of each 3 or 4 week cycle depending on the selected ICI agent. Administration of ICI will continue past the 24 week timepoint per discretion of the investigator.

Drugs: Sarilumab, ICI Therapy

Sites

1 site in 1 country

  • Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland, United States